StreetInsider.com News Articles

Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer

Tue, 01 Sep 2026 16:04:34 -0400

Oppenheimer analyst Leland Gershell raised the price target on Ascendis Pharma (NASDAQ: ASND) to $312.00 (from $304.00) while maintaining a Outperform rating.

The analyst comments "We have revised our ASND model to reflect terms agreed to w/BMRN around Yuviwel as announced yesterday. Although the royalty rates to be paid are above our prior projections, these obligations will end much earlier than we had modeled—having a net positive impact to our valuation perspective. We raise our PT to $312 (from 304). Binding term sheet for global settlement. In exchange for BMRN agreeing to grant ASND a non-exclusive, global license to commercialize Yuviwel,

Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer

Tue, 01 Sep 2026 16:04:34 -0400

Oppenheimer analyst Leland Gershell raised the price target on Ascendis Pharma (NASDAQ: ASND) to $312.00 (from $304.00) while maintaining a Outperform rating.

Ascendis Pharma (ASND) PT Lowered to $273 at Morgan Stanley

Tue, 01 Sep 2026 08:07:49 -0400

Morgan Stanley analyst Maxwell Skor lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $273.00 (from $275.00) while maintaining a Overweight rating.

Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities

Tue, 01 Sep 2026 06:59:16 -0400

BofA Securities analyst Tazeen Ahmad lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $304.00 (from $306.00) while maintaining a Buy rating.

The analyst comments "Ascendis (ASND) entered a binding term sheet with BioMarin (BMRN; covered by Jason Gerberry) for a global settlement and royalty-bearing license related to Yuviwel. Although the associated royalties reduce Yuviwel economics, we view the agreement as a reasonable resolution to the dispute and note a negotiated settlement was a likely outcome. The agreement eliminates the risk of disruption to US supply or commercialization, consistent with our prior view that litigation concerns were overdone. We also

Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities

Tue, 01 Sep 2026 06:59:16 -0400

BofA Securities analyst Tazeen Ahmad lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $304.00 (from $306.00) while maintaining a Buy rating.

Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies

Mon, 31 Aug 2026 08:51:31 -0400

Jefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $330.00 (from $333.00) while maintaining a Buy rating.

The analyst comments "We think investors will be relieved to see a settlement with BMRN resulting in time-limited royalties on Yuviwel sales. The royalty rate (20% US, 18% EU/ Korea/Brazil) may come in on the higher end of expectations, but bigger picture this is an overhang removed and we think that matters more. All patent-related proceedings btwn the parties now resolved and we think that allows investors and strategics to focus on the fundamentals."

Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies

Mon, 31 Aug 2026 08:51:31 -0400

Jefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $330.00 (from $333.00) while maintaining a Buy rating.

Ascendis Pharma (ASND) PT Lowered to $326 at Stifel

Mon, 31 Aug 2026 08:10:19 -0400

Stifel analyst Alex Thompson lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $326.00 (from $328.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)

Mon, 31 Aug 2026 06:49:49 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $345.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented: "The United States International Trade Commission (USITC) August 14 order moved the final initial determination to October 1, 2026 and the ultimate action date to February 1, 2027, citing case complexity and judicial-resource constraints. A subsequent 60-day presidential review would extend final resolution to around April 1. Under the limited-exclusion scenario described by Ascendis, those on YUVIWEL by February 1, 2027 would be eligible to stay on therapy even if subsequent new U.S. starts were restricted, with the worst-case

H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy

Thu, 27 Aug 2026 06:55:18 -0400

(Updated - August 27, 2026 6:55 AM EDT)

H.C. Wainwright analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Buy rating and a price target of $345.00.

The analyst comments "We are more bullish vs. Street on YUVIWEL and similarly optimistic as Street on YORVIPATH. We initiate coverage of Ascendis Pharma with a Buy rating and 12-month price target of $345 per share. At 8.8x NTM revenue vs. a 11.6x peer median (35.3x mean), we believe the market underprices a YUVIWEL launch entering a proven >$1B achondroplasia (ACH) market with only 52 jabs per year vs. 365. VOXZOGO

H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy

Thu, 27 Aug 2026 06:55:18 -0400

(Updated - August 27, 2026 6:55 AM EDT)

H.C. Wainwright analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Buy rating and a price target of $345.00.

Ascendis to present 2-year navepegritide trial data at ISDS 2026

Tue, 25 Aug 2026 16:01:32 -0400

Ascendis Pharma A/S (Nasdaq: ASND) announced it will present Week 104 data from the ApproaCH pivotal trial of once-weekly TransCon CNP (navepegritide) at the International Skeletal Dysplasia Society annual meeting in Toronto, Canada, running August 26-29, 2026.

The oral presentation, titled "Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension," is scheduled for August 28 and will be delivered by Carlos Bacino, M.D., Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children's Hospital.

Ascendis will also display a poster throughout the conference examining a number needed to harm

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Tue, 25 Aug 2026 16:01:00 -0400

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital.

“This long-term data reinforces the benefits seen in clinical trials of

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Tue, 25 Aug 2026 16:01:00 -0400

“This long-term data reinforces the benefits seen in clinical trials of

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Tue, 25 Aug 2026 16:01:00 -0400

“This long-term data reinforces the benefits seen in clinical trials of

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Tue, 25 Aug 2026 16:01:00 -0400

“This long-term data reinforces the benefits seen in clinical trials of

BMO Capital Starts Ascendis Pharma (ASND) at Outperform

Wed, 19 Aug 2026 05:29:16 -0400

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Outperform rating, PT $319.00.

The analyst comments "We initiate coverage of Ascendis at Outperform with a $319 target price. Ascendis has delivered three FDA approvals with its proprietary TransCon platform — SKYTROFA in pediatric and adult growth hormone deficiency (GHD), YORVIPATH in chronic hypoparathyroidism (HPTH), and YUVIWEL in achondroplasia. The platform is living up to its promise of becoming a repeatable development engine that lessens development risk and increases the probability of success (PoS) on successive programs. The near- term investment case is to be carried by

BMO Capital Starts Ascendis Pharma (ASND) at Outperform

Wed, 19 Aug 2026 05:29:16 -0400

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Outperform rating, PT $319.00.

Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946063.html

Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946063.html

Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946063.html

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

Tue, 18 Aug 2026 08:00:00 -0400

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection

Milestone marks Eyconis’ transition to a clinical-stage biotechnology company

REDWOOD CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a biotechnology company developing next-generation, long-acting ophthalmic therapeutics, today announced the initiation of OVERTURE, the company’s first-in-human Phase 1b/2a clinical trial of EYC-0305 in treatment-naïve patients with neovascular, or wet, age-related macular degeneration (AMD). The first patients have been dosed in the study, marking Eyconis’ transition

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

Tue, 18 Aug 2026 08:00:00 -0400

Milestone marks Eyconis’ transition to a clinical-stage biotechnology company

Ascendis Pharma (ASND) PT Raised to $341 at TD Cowen

Fri, 14 Aug 2026 08:50:49 -0400

TD Cowen analyst Yaron Werber raised the price target on Ascendis Pharma (NASDAQ: ASND) to $341.00 (from $325.00) while maintaining a Buy rating.

Ascendis Pharma (ASND) PT Raised to $290 at RBC Capital

Fri, 14 Aug 2026 08:41:47 -0400

RBC Capital analyst Luca Issi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $290.00 (from $280.00) while maintaining a Outperform rating.